Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Diabetes Management put to the ‘Quo-Test’

Published: Wednesday, August 15, 2012
Last Updated: Wednesday, August 15, 2012
Bookmark and Share
A simple, accurate and reliable HbA1c near patient analyser from EKF Diagnostics and Stanbio Laboratory.

EKF Diagnostics has developed Quo-Test, for easy and reliable measurement of glycated haemoglobin (HbA1c) used in the detection and management of diabetes.  The device, which is awaiting FDA clearance with a launch expected early in 2013, will be sold in North, Central and South America by Stanbio Laboratory, a Texas based specialist distributor of IVD products and clinical chemistry manufacturer. Stanbio was acquired by EKF Diagnostics in May 2011.EFK-1.gif

Quo-Test enables clinicians to make a rapid determination of diabetes management , thereby improving patients’ experience, thanks to the fast and accurate results obtained from the machine in just four minutes from 4μl of blood from finger prick or venous sample. The user-friendly device has a multi-lingual menu and allows for efficient data handling, with a barcode reader and storage of up to 7,000 results, which can be downloaded to a computer via a USB port.

Quo-Test uses a patented Boronate Fluorescence Quenching Technology (BFQT): a simple, fast and accurate method, based on the well-documented boronate affinity for glycated haemoglobin, which is not affected by haemoglobin variants. Although Quo-Test has been developed to be used in a point of care setting, it is a professional product providing laboratory level accuracy, reporting its results in IFCC and DCCT standards (Mono S & JDS reporting are also available). The CE marked analyser has been approved by China's SFDA for the monitoring of HbA1c in diabetes patients and is manufactured in the UK by EKF Diagnostics Group company Quotient Diagnostics Ltd (ISO13485:2003 certified).

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos